Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen, HTG Molecular Begin Second CDx Development Project

NEW YORK (GenomeWeb) – Qiagen and HTG Molecular Diagnostics have agreed to a second development program under their previously announced master assay development, commercialization, and manufacturing agreement.

As part of the program announced today, HTG Molecular and Qiagen Manchester, a wholly owned subsidiary of Qiagen, will use HTG EdgeSeq technology to develop gene expression profiling assays for use with next-generation sequencing technology to support an unnamed pharmaceutical company's therapeutic development and commercialization programs.

"We are very pleased with the early results of our partnership with Qiagen and are encouraged by customer reception to our joint capabilities, which provide a complete NGS solution from biomarker development to full companion diagnostic commercialization," HTG President and CEO TJ Johnson said in a statement.

"With two new programs realized from the Qiagen partnership to date, HTG now has three distinct clinical assay development programs underway, including two that we believe could lead to regulatory filings for companion diagnostics during 2018," Johnson added.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.